Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OCUL – Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.
OCUL
$12.41
Name : Ocular Therapeutix, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,629,731,584.00
EPSttm : -1.26
finviz dynamic chart for OCUL
Ocular Therapeutix, Inc.
$12.41
7.73%
$0.89

Float Short %

8.61

Margin Of Safety %

Put/Call OI Ratio

0.36

EPS Next Q Diff

0.03

EPS Last/This Y

-0.21

EPS This/Next Y

0.01

Price

11.52

Target Price

21.31

Analyst Recom

1.08

Performance Q

7.06

Relative Volume

1.46

Beta

1.54

Ticker: OCUL




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08OCUL12.720.170.1159409
2025-09-09OCUL12.750.190.0258087
2025-09-10OCUL13.060.190.1358617
2025-09-11OCUL12.770.190.1458112
2025-09-12OCUL12.810.190.0758691
2025-09-15OCUL12.530.190.0158772
2025-09-16OCUL12.440.220.0360213
2025-09-17OCUL12.160.214813323940830.3057996485061560358
2025-09-18OCUL12.70.221.4060338
2025-09-22OCUL12.190.220.7945554
2025-09-23OCUL12.250.260.7647382
2025-09-24OCUL12.570.281.1148733
2025-09-25OCUL12.250.300.0250516
2025-09-26OCUL12.520.303.7550727
2025-09-29OCUL12.530.380.2355075
2025-09-30OCUL11.690.390.2756200
2025-10-01OCUL11.050.400.7458942
2025-10-02OCUL11.050.390.0661517
2025-10-03OCUL11.370.380.8262425
2025-10-06OCUL10.970.370.0262719
2025-10-07OCUL11.530.360.0564622
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08OCUL12.71-70.4- -1.49
2025-09-09OCUL12.74-70.4- -1.49
2025-09-10OCUL13.06-70.4- -1.49
2025-09-11OCUL12.77-70.4- -1.49
2025-09-12OCUL12.81-70.4- -1.49
2025-09-15OCUL12.53-70.4- -1.49
2025-09-16OCUL12.44-70.4- -1.49
2025-09-17OCUL12.16-70.4- -1.49
2025-09-18OCUL12.70-70.4- -1.49
2025-09-19OCUL12.08-70.4- -1.49
2025-09-22OCUL12.20-70.4- -1.49
2025-09-23OCUL12.25-70.4- -1.49
2025-09-24OCUL12.57-70.4- -1.49
2025-09-25OCUL12.24-70.4- -1.49
2025-09-26OCUL12.53-70.4- -1.49
2025-09-29OCUL12.53-70.4- -1.49
2025-09-30OCUL11.70-70.4- -1.49
2025-10-01OCUL11.05-70.4- -1.49
2025-10-02OCUL11.04-63.6- -1.47
2025-10-03OCUL11.39-63.6- -1.47
2025-10-06OCUL10.97-57.6- -1.43
2025-10-07OCUL11.52-57.6- -1.43
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08OCUL-0.2217.768.97
2025-09-09OCUL-0.2217.768.97
2025-09-10OCUL-0.2217.768.97
2025-09-11OCUL-0.2217.769.49
2025-09-12OCUL-0.2217.769.49
2025-09-15OCUL-0.2217.899.49
2025-09-16OCUL-0.2217.899.49
2025-09-17OCUL-0.2217.899.49
2025-09-18OCUL-0.2217.899.49
2025-09-19OCUL-0.2217.899.49
2025-09-22OCUL-0.2217.919.49
2025-09-23OCUL-0.2217.919.49
2025-09-24OCUL-0.2217.919.49
2025-09-25OCUL-0.2217.9110.48
2025-09-26OCUL-0.2217.9110.48
2025-09-29OCUL-0.2217.9110.48
2025-09-30OCUL-0.2217.9110.48
2025-10-01OCUL-0.2217.9110.48
2025-10-02OCUL-0.2217.9110.48
2025-10-03OCUL-0.2217.9110.48
2025-10-06OCUL-0.1810.540
2025-10-07OCUL-0.2410.548.61
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.39

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.36

Insider Transactions

-0.24

Institutional Transactions

10.54

Beta

1.54

Average Sales Estimate Current Quarter

14

Average Sales Estimate Next Quarter

16

Fair Value

Quality Score

40

Growth Score

41

Sentiment Score

39

Actual DrawDown %

52.6

Max Drawdown 5-Year %

-90.9

Target Price

21.31

P/E

Forward P/E

PEG

P/S

43.08

P/B

6.51

P/Free Cash Flow

EPS

-1.28

Average EPS Est. Cur. Y​

-1.43

EPS Next Y. (Est.)

-1.41

Target Price Estimates Raised

2

Target Price Estimates Lowered

Profit Margin

-382.51

Relative Volume

1.46

Return on Equity vs Sector %

-96

Return on Equity vs Industry %

-82.4

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.07

EBIT Estimation

Ocular Therapeutix, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 274
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today
news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance
stock history OCUL – Ocular Therapeutix, Inc. invest stock market
stock prices OCUL premarket after hours
ticker OCUL fair value insiders trading